Boyce Sarah
SEC Form 4 insider trading activity
Boyce Sarah has filed 7 SEC Form 4 filings (36 transaction rows) across 2 companies, including RNA, RNAM, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Sep 22, 2026.
On the most recent filing, Boyce Sarah is listed as President and CEO at Avidity Biosciences, Inc. Inside the rolling window, Boyce Sarah reported no open-market purchases and 2 open-market sales totaling $1.7M in RNA. The largest disclosed transaction in the window is a sale of 14,387 RNA shares on Jan 21, 2026, worth $1.0M.
Companies traded
Other insiders at RNA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.7M
reported sales (SEC code S)
Companies
2
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Boyce Sarah made?
Boyce Sarah has filed 7 SEC Form 4 filings (36 transaction rows) across 2 companies, including RNA, RNAM since 2025.
Which companies does Boyce Sarah trade?
Boyce Sarah has filed SEC Form 4 disclosures for 2 companies, including RNA, RNAM.
When was Boyce Sarah's most recent SEC Form 4 filing?
Boyce Sarah's most recent SEC Form 4 filing on Tracefour is dated Sep 22, 2026.
What is Boyce Sarah's total buy and sell value in the current window?
Inside the rolling retention window, Boyce Sarah bought $0 and sold $1.7M based on SEC Form 4 filings.
What was Boyce Sarah's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 14,387 RNA shares on 2026-01-21, worth $1.0M, per SEC Form 4 filings.